Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VANIBullishIndustry Newsnews

High materiality7/10

Vivani gains Australian approval to begin SLIM-1 GLP-1 implant trial

Jun 25, 2026, 7:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Direct regulatory-approval milestone for a key trial; potential readouts mid-2026 could re-rate risk-adjusted value of Vivani's GLP-1 implant platform.

AI summary

What happened, with direct paths to the underlying reporting

Vivani Medical announced Bellberry approval to initiate SLIM-1, a Phase 1 trial of NPM-139 semaglutide implant in Australia, with mid-2026 initiation expected. This follows the 2025 NPM-119 exenatide implant study and sets the stage for SLIM-2 if SLIM-1 shows favorable signals, potentially accelerating the GLP-1 implant program and expanding addressable obesity therapies.

HREC Bellberry approves SLIM-1 Phase 1 for NPM-139 semaglutide implant.
Initiation targeted for mid-2026; builds on 2025 NPM-119 exenatide implant results.
SLIM-1 is open-label, randomized, active comparator-controlled; n=20 total (10 per group).
SLIM-2 may follow if SLIM-1 is favorable, focusing on dose-ranging efficacy.
Vivani touts demand for miniature, reversible GLP-1 implants.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.